ORCID Profile
0000-0001-9511-7380
Current Organisation
John Hunter Hospital
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 02-2021
DOI: 10.1002/UEG2.12053
Publisher: Wiley
Date: 28-04-2020
DOI: 10.1111/LIV.14478
Publisher: Elsevier BV
Date: 10-2020
Publisher: Wiley
Date: 08-2019
DOI: 10.1111/IMJ.14389
Abstract: Eosinophilic oesophagitis (EoE) is now a well-recognised cause of dysphagia and food bolus obstruction (FBO). The diagnosis requires histologic confirmation, and the yield is greatest when at least 4 to 6 oesophageal biopsies are taken from different sites. Previous case reports of FBO have demonstrated a low biopsy rate, and as such cases of EoE may have been missed. In this review, the medical records of 123 patients aged 18 years or older, who had presented with FBO over a 2 year period, were reviewed. EoE was the most common diagnosis, and was found in 81.3% of patients with FBO aged 40 years or less. 45.5% of patients with FBO were biopsied, and of those, 33.9% were confirmed to have had at least 4 biopsies. EoE is a common cause of FBO and requires appropriate oesophageal s ling to confirm the diagnosis. Cases of EoE may otherwise be missed.
Publisher: Wiley
Date: 03-1998
DOI: 10.1111/J.1440-1746.1998.01550.X
Abstract: The treatment of chronic hepatitis C is relatively unsatisfactory and many patients have turned to unproven alternative medicines to modify the course of their illness. We report a study of a Chinese herbal medicine preparation CH-100 in the management of chronic hepatitis C. Patients with documented chronic hepatitis C were randomly allocated to receive active herbal or placebo tablets (five tablets thrice daily). Patients were followed monthly and evaluated by a Western and a traditional Chinese medical practitioner. Therapy was monitored by measurement of liver function tests, creatinine and full blood count on a monthly basis. Twenty patients in each group were well matched for age, sex, duration of illness, previous interferon therapy and alcohol intake. Active Chinese herbal medication was associated with a significant reduction in alanine aminotransferase (ALT) levels over the 6 month study period (P < 0.03). No patient cleared the virus but four normalized their ALT on treatment. Appropriately prescribed Chinese herbal medicine may have a role in the management of chronic hepatitis C and further controlled studies are indicated.
Publisher: Elsevier BV
Date: 2017
Publisher: BMJ
Date: 04-06-2020
Publisher: Wiley
Date: 09-1996
DOI: 10.1080/09595239600186031
Abstract: Hepatitis B remains a major public health problem around the world. The discovery of the hepatitis C virus has erted interest from hepatitis B to this new virus and the epidemic associated with it, but hepatitis B remains a significant pathogen for millions of people worldwide. The World Health Organization has suggested that universal vaccination of children against hepatitis B should be implemented in an attempt to reduce the enormous morbidity and mortality associated with infection of this virus group. The review seeks to identify all the newer discoveries relating to hepatitis B that have been made in the past decade. Reference is made to the appearance of hepatitis B mutants which are able to infect patients previously infected with the wild strain of the virus. The implications of mutants on vaccination programmes is raised, as are issues relating to treatment of hepatitis B infection.
Publisher: Elsevier BV
Date: 2016
Publisher: Elsevier BV
Date: 08-2020
Publisher: Elsevier BV
Date: 05-2017
Publisher: Wiley
Date: 22-07-2020
DOI: 10.1111/JGH.15178
Abstract: The global pandemic of coronavirus disease‐2019 (COVID‐19) has led to significant disruptions in healthcare delivery. Patients with chronic liver diseases require a high level of care and are therefore particularly vulnerable to disruptions in medical services during COVID‐19. Recent data have also identified chronic liver disease as an independent risk factor for COVID‐19 related hospital mortality. In response to the pandemic, national and international societies have recommended interim changes to the management of patients with liver diseases. These modifications included the implementation of telehealth, postponement or cancelation of elective procedures, and other non‐urgent patient care‐related activities. There is concern that reduced access to diagnosis and treatment can also lead to increased morbidity in patients with liver diseases and we may witness a delayed surge of hospitalizations related to decompensated liver disease after the COVID‐19 pandemic has receded. Therefore, it is paramount that liver practices craft a comprehensive plan for safe resumption of clinical operations while minimizing the risk of exposure to patients and health‐care professionals. Here, we provide a broad roadmap for how to safely resume care for patients with chronic liver disease according to various phases of the pandemic with particular emphasis on outpatient care, liver transplantation, liver cancer care, and endoscopy.
Publisher: Informa UK Limited
Date: 12-2021
DOI: 10.2147/CEG.S282699
Publisher: Wiley
Date: 21-07-2020
DOI: 10.1111/JGH.15159
Publisher: Humana Press
Date: 24-08-2011
Publisher: BMJ
Date: 16-03-2021
Publisher: Wiley
Date: 22-04-2020
DOI: 10.1111/JGH.15053
Publisher: Elsevier BV
Date: 07-2013
No related grants have been discovered for Steven Bollipo.